Glenn L Md Cooper Net Worth

The estimated Net Worth of Glenn L Md Cooper is at least $5.46 Milhão dollars as of 23 May 2019. Glenn Cooper owns over 5,000 units of Repligen stock worth over $5,120,671 and over the last 15 years Glenn sold RGEN stock worth over $334,700.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Glenn Cooper RGEN stock SEC Form 4 insiders trading

Glenn has made over 3 trades of the Repligen stock since 2009, according to the Form 4 filled with the SEC. Most recently Glenn sold 5,000 units of RGEN stock worth $334,700 on 23 May 2019.

The largest trade Glenn's ever made was buying 10,000 units of Repligen stock on 21 September 2012 worth over $60,900. On average, Glenn trades about 1,250 units every 218 days since 2009. As of 23 May 2019 Glenn still owns at least 35,709 units of Repligen stock.

You can see the complete history of Glenn Cooper stock trades at the bottom of the page.

What's Glenn Cooper's mailing address?

Glenn's mailing address filed with the SEC is 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453.

Insiders trading at Repligen

Over the last 22 years, insiders at Repligen have traded over $118,224,292 worth of Repligen stock and bought 160,440 units worth $1,459,521 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Glenn P Muir, eWalter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of $3,015,702. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth $1,139,034.

What does Repligen do?

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.

Complete history of Glenn Cooper stock trades at Repligen

Repligen executives and stock owners

Repligen executives and other stock owners filed with the SEC include:

• Anthony Hunt,
  President, Chief Executive Officer, Director
• Jon Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Senior Vice President - Research and Development
• Anthony J. Hunt,
  CEO, Pres & Director
• Jon K. Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Sr. VP of R&D
• Karen Dawes,
  Independent Chairperson of the Board
• Glenn Muir,
  Independent Director
• Thomas Ryan,
  Independent Director
• Nicolas Barthelemy,
  Independent Director
• Rohin Mhatre,
  Independent Director
• Carrie Eglinton,
  Director
• James Slaughter,
  Chief HR Officer
• James R. Bylund,
  Chief Operating Officer
• Christine Gebski,
  Sr. VP of Filtration & Chromatography
• Ken Elmer,
  Global Head of HR
• Rachel Goodrich,
  VP of Marketing
• Stephen Tingley,
  VP of Global Sales
• Squire Servance,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Sondra S. Newman,
  Global Head of Investor Relations
• Jim Bylund,
  Sr. VP of Operations & Information Technology
• Jason K Garland,
  CFO
• Glenn L Md Cooper,
  Director
• James R Rusche,
  Senior Vice President
• John Cox,
  Director
• Howard Benjamin,
  
• Roy T Eddleman,
  10% owner
• Christine Gebski,
  See Remarks
• G William Miller,
  Director
• Timothy Scott Harris,
  
• Barbara Burnim Day,
  Vice President
• Daniel W Muehl,
  CFO
• Partners L P/Ilbiotechnolog...,
  
• Alfred Lewis Goldberg,
  Director
• Walter C Herlihy,
  PRESIDENT, CEO
• Michael A Griffith,
  Director
• Daniel P Witt,
  Vice President
• Jonathan I Lieber,
  CFO
• Earl Webb Henry,
  Director
• William J Kelly,
  Vice President
• Alexander Rich,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Hal Landy,
  Vice President
• Paul Schimmel,
  Director
• Laura Whitehouse,
  Vice President
• Robert J Hennessey,
  Director
• Margaret Pax,
  
• Konstantin Konstantinov,
  
• Martin D Madaus,
  
• James Bylund,
  Chief Operating Officer
• Olivier Loeillot,
  Chief Executive Officer